

30 Oct 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: BMS looks to new launches amid patent losses; Novartis prioritizes high-value medicines and the US market; Biogen learns from Aduhelm experience; J&J builds myeloma franchise; and Asian bioventures debate best strategies.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 28 October 2022, including: [Bristol Myers Squibb Company](#) looks to new launches amid patent losses; [Novartis AG](#) prioritizes high-value medicines and the US market; [Biogen, Inc.](#) learns from Aduhelm experience; [Johnson & Johnson](#) builds myeloma franchise; and Asian bioventures debate best strategies.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[All Eyes On Bristol's New Launches](#)" - Scrip, 26 Oct, 2022.)

(Also see "[Weak Spots Blight Novartis Third Quarter As New Products Shine](#)" - Scrip, 25 Oct, 2022.)

(Also see "[Biogen Weighs Aduhelm Lessons Ahead Of Lecanemab Launch](#)" - Scrip, 25 Oct, 2022.)

(Also see "[J&J Adds Second Anti-BCMA Myeloma Therapy In US With Tecvayli Approval](#)" - Scrip, 26 Oct, 2022.)

(Also see "[*How Do Bioventures Thrive In APAC? Strategies And Risks Beyond Borders*](#)" - Scrip, 24 Oct, 2022.)

[Click here to explore this interactive content online](#) ✨